International Journal of Medical Science and Clinical Research Studies

ISSN(print): 2767-8326, ISSN(online): 2767-8342

Volume 03 Issue 04 April 2023

Page No: 644-647

DOI: https://doi.org/10.47191/ijmscrs/v3-i4-13, Impact Factor: 6.597

Dermatological and Cardiac Manifestations of Wegener's Disease

Manuel Enrique Vadillo Flores[1], Miguel Ángel Sánchez Dorantes[2], María Erika Boza Medrano[3], María Fernanda Guijosa Ortega[4], Paola Daniela Guerrero Ramírez[5], Omar Alejandro Avila Hernández[6]

[1]Universidad Autónoma de Guadalajara. Guadalajara, México.
[2]Universidad Autónoma de Querétaro. Santiago de Querétaro, México.
[3]Hospital General de Zona #1 del Instituto Mexicano del Seguro Social. Durango, México.
[4]Hospital de especialidades Dr.Belisario Dominguez. Iztapalapa, Ciudad de México, México.
[5]Hospital General Regional 1, Instituto Mexicano del Seguro Social, Orizaba, Veracruz, México.
[6]Universidad Autónoma de Querétaro. Santiago de Querétaro, México.

ABSTRACT

Wegener's disease, also known as Granulomatosis with Polyangiitis (GPA), is a rare autoimmune disorder that affects small- to medium-sized blood vessels, causing inflammation and damage to various organs. The disease commonly involves the respiratory tract, kidneys, and the skin. In terms of dermatological symptoms, patients may develop purpura, which are small red or purple spots on the skin caused by bleeding under the skin, or nodules or ulcers that may be painful or non-painful. These lesions can occur anywhere on the body but are often found on the lower legs. Vascular involvement can lead to necrotizing vasculitis, which can be life-threatening if not treated promptly. Early diagnosis and treatment with immunosuppressive therapy can help manage the symptoms and prevent organ damage.

ARTICLE DETAILS

Published On:
06 April 2023

Available on:
https://ijmscr.org/

INTRODUCTION

Wegener's granulomatosis (WG) also known as granulomatosis with polyangiitis is a rare autoimmune disease that affects multiple body systems, including the upper respiratory tract, lungs, kidneys and blood vessels. It was first described in 1936 by the German pathologist Friedrich Wegener and is characterized by the presence of necrotic granulomas and vasculitis. The disease is most common in middle-aged people and a prevalence of 3 to 15 cases per million population has been found. WG affects men and women equally and occurs more frequently in people of Caucasian descent. Although WG is a rare disease, it can have serious health consequences for patients, especially when it presents in severe forms or when it is not adequately treated.1,2

EPIDEMIOLOGY

WG is a rare disease with a low incidence and prevalence. The annual incidence of WG in the United States is estimated to be 1-2 cases per million people. The disease affects men and women equally, with a median age of disease onset of about 40 years. WG has also been associated with a higher prevalence in people of Caucasian descent compared to other ethnicities. In addition, an increase in the incidence of WG has been observed in recent years, suggesting a possible increase in awareness and diagnosis of the disease.3

CARDIAC MANIFESTATIONS

WG can affect the heart in different ways, and manifestations can vary widely among patients. Some patients may have subclinical cardiac involvement, with no obvious symptoms, while others may develop severe symptoms of heart failure or arrhythmias.4 Cardiac manifestations of WG may include:

Pericarditis: inflammation of the pericardium. It can cause chest pain, shortness of breath, and fluid accumulation around the heart (pericardial effusion).5

Myocarditis: inflammation of the heart muscle. May cause chest pain, fatigue, shortness of breath and arrhythmias.5

Endocarditis: inflammation of the heart valves. May cause heart murmurs, fever and other symptoms of infection.5
Aortic aneurysm: abnormal dilatation of the aorta. May cause chest pain, dyspnea and risk of rupture.5

Coronary artery disease: inflammation of the coronary arteries can cause narrowing or blockage of the coronary

arteries, which can lead to angina pectoris, myocardial infarction and other cardiovascular complications.6

Heart failure: chronic inflammation of the heart can cause heart muscle weakness and ventricular dysfunction, which can lead to fatigue, dyspnea, lower limb edema and other symptoms of heart failure.6

DIAGNOSIS OF THE CARDIAC MANIFESTATIONS OF WEGENER'S GRANULOMATOSIS

Diagnosis of the cardiac manifestations of WG can be difficult, as symptoms may be nonspecific and the disease may mimic other cardiac pathologies. Diagnosis is based on a combination of clinical evaluation, imaging tests, and laboratory tests.7 Diagnostic tests may include:

-Electrocardiogram (ECG): may show changes in heart rhythm or ventricular function.8
-Echocardiography: may show the presence of pericardial effusion, alterations in cardiac function or valvular abnormalities.8
-Computed tomography (CT) or magnetic resonance imaging (MRI) of the thorax: may show the presence of aortic aneurysms.8

Cardiac catheterization: may be necessary to evaluate the presence of aortic aneurysms or to obtain an endomyocardial biopsy in cases of myocarditis or endocarditis.8

Blood tests: Laboratory tests can help identify signs of systemic inflammation and rule out other causes of cardiac symptoms. Blood tests may include measurement of C-reactive protein (CRP) levels, erythrocyte sedimentation rate (ESR), anti-neutrophil cytoplasmic antibodies (ANCA) and other markers of inflammation.9

TREATMENT OF CARDIAC MANIFESTATIONS OF WEGENER'S GRANULOMATOSIS

Treatment of the cardiac manifestations of WG depends on the type and severity of cardiac lesions and may include a combination of medical therapies and invasive procedures.9 Some treatment options may include:

Corticosteroids: Corticosteroids are an immunosuppressive therapy commonly used to control inflammation in WG. 9
Immunosuppressants: immunosuppressants, such as methotrexate, azathioprine or mycophenolate mofetil, can be used in combination with corticosteroids to control inflammation and prevent disease relapse.9

Antithrombotic therapy: patients with aortic aneurysms may require antithrombotic therapy to prevent the formation of blood clots in the aorta.9

Surgical procedures: in severe cases, cardiac surgery may be necessary to repair or replace heart valves or to correct aortic aneurysms.9

Dermatological manifestations

WG can also affect the skin in a number of ways, including the appearance of nodules, ulcers and vasculitis. Skin involvement in WG occurs in about 50% of patients and can be an early sign of the disease. Nodules and ulcers can occur anywhere on the body, but are most common on the face, hands and feet. Cutaneous vasculitis may present as a rash or as lesions that look like blisters or ulcers.10

Dermatologic manifestations of Wegener's granulomatosis

Wegener's granulomatosis (WG) is an autoimmune disease that can affect multiple organs and body systems, including the skin. The dermatologic manifestations of WG can vary in clinical presentation and may be one of the earliest signs of the disease. 11 Some of the most common dermatologic manifestations of WG include:

Cutaneous nodules: Cutaneous nodules are a common manifestation of WG and can vary in size and shape. Nodules can be painful or painless and can be single or multiple. Skin nodules can ulcerate and form chronic ulcers that are difficult to heal.11
Palpable purpura: Palpable purpura is a type of skin lesion that presents as purplish spots on the skin. Palpable purpura is the result of inflammation of blood vessels in the skin and can be an early sign of WG.12
Cutaneous vasculitis: Cutaneous vasculitis is an inflammation of blood vessels in the skin and can be a cutaneous manifestation of WG. Cutaneous vasculitis may present as papular or nodular lesions, ulcers, or areas of cutaneous ischemia.12
Vesicular lesions: Vesicular lesions may present as small blisters on the skin and may be a cutaneous manifestation of WG. Vesicular lesions can be painful and may rupture, leaving ulcerated areas on the skin.12
Purpuric lesions: Purpuric lesions are a rare cutaneous manifestation of WG and present as purpuric lesions on the skin. Purpuric lesions are the result of inflammation of blood vessels in the skin and may be associated with more severe systemic vasculitis.12

The diagnosis of cutaneous involvement in WG can be difficult due to the similarity of the lesions with other diseases. Biopsies of skin lesions are recommended to establish the diagnosis. Imaging, such as computed tomography (CT) and magnetic resonance imaging (MRI), can help identify subcutaneous skin lesions and rule out other diseases that may cause similar symptoms.
In addition, it is important to perform laboratory tests for the presence of anti-neutrophil cytoplasmic antibodies (ANCA), which are found in the majority of patients with WG.12,13,14

TREATMENT OF DERMATOLOGICAL MANIFESTATIONS OF WEGENER'S GRANULOMATOSIS

Photodynamic therapy: Photodynamic therapy (PDT) is a treatment that uses a combination of a photosensitizer and a light source to destroy abnormal cells. Some studies have found that PDT can be effective in the treatment of cutaneous lesions of WG.15

Cryotherapy: Cryotherapy is a treatment that uses liquid nitrogen to freeze and destroy skin lesions. Cryotherapy can be effective in the treatment of WG skin lesions, although it can be painful and leave scars.16

Laser therapy: Laser therapy is a treatment that uses high-energy light to destroy abnormal cells. Laser therapy can be effective in the treatment of WG skin lesions, although it can be expensive and may require multiple treatment sessions.17

In addition to these treatment options, it is important to treat the dermatologic manifestations of WG in the context of overall disease management. Immunosuppressive therapy and biologic therapy can be effective in the treatment of the dermatologic manifestations of WG, as well as in the prevention of systemic complications of the disease. Treatment of cutaneous involvement in WG depends on the severity of the disease. Patients with mild disease may receive NSAIDs or topical glucocorticoids. Patients with more severe disease.18,19

CONCLUSIONS

Dermatologic manifestations: Cutaneous manifestations of WG can vary in severity and may include ulcers, nodules, and vasculitis. Diagnosis is based on a combination of clinical and laboratory findings, such as skin biopsy and serum ANCA levels. Treatment includes a variety of options, such as corticosteroids, immunosuppressants, biological therapy, photodynamic therapy, cryotherapy and laser therapy. It is important to treat the dermatologic manifestations of WG in the context of overall disease management to prevent systemic complications.

Cardiac manifestations: Cardiac manifestations of WG may include pericarditis, myocarditis, endocarditis and vasculitis. Diagnosis is based on a combination of clinical and laboratory findings, such as echocardiography and serum ANCA levels. Treatment includes a variety of options, such as corticosteroids, immunosuppressants, biologic therapy and specific treatment for the underlying cardiac condition. It is important to treat the cardiac manifestations of WG early and aggressively to prevent serious complications, such as heart failure.

In general, Wegener's granulomatosis is a systemic disease that can affect several organs and systems, including the skin and heart. Diagnosis is based on a combination of clinical and laboratory findings, and treatment depends on the severity and extent of the disease. It is important to treat the dermatologic and cardiac manifestations of WG aggressively and in the context of overall disease management to prevent serious complications and improve patients' quality of life. Continued research into the pathogenesis and treatment of WG may help to improve the understanding and management of this complex disease.

REFERENCES

I. Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med 1983; 98: 76-85
II. Autoantibodies against neutrophils and monocytes: tool for diagnosis and marker of disease activity in Wegener's granulomatosis. Lancet 1985; 1: 425-429.
III. Wegener's granulomatosis: observations on 18 patients with severe renal disease. Q J Med 1983; 208: 435-460.
IV. Cardiac complications of Wegener's granulomatosis: a case report of complete heart block and review of the literature. Semin Arthritis Rheum 1980; 10: 148-154.
V. Wegener's granulomatosis and the heart. Br Heart J 1994; 71: 82-86.
VI. Reversible valvulitis in Wegener's granulomatosis. Chest 1987; 92: 182-183
VII. Myocardial infarction in Wegener's Granulomatosis. Aust NZ J Med 1976; 6: 336-340.
VIII. The Churg-Strauss syndrome. A case report with angiographically documented coronary involvement and a review of the literature. Chest 1995; 107: 578-580.
IX. Wegener's granulomatosis-report of four cases including two in patients who died of myocardial infarction. Nippon Kyobu Shikkan Gakkai Zasshi 1994; 3: 988-993.
X. Vera-Lastra OL, Halabe-Cherem J, Jara LJ. Systemic vasculitis. General concepts. In: Vera-Lastra OL, Halabe-Cherem J, eds. Vasculitis. Mexico: Alfil; 2006. pp. 1-4.
XI. Klinger H. Grenzformen der periarteritis nodosa. Frankf Ztschr Pathol 1931;42:455-480.
XII. Wegener F. Uber eine eigenartige rhinogene granulomatose mit besonderer beteilingung des arteriensystems und der neiren. Beitr Pathol Anat Allg Pathol 1939;102:36-68.
XIII. Goodman GC, Churg J. Wegener's granulomatosis: pathology and review of the literature. Arch Pathol 1954;58:533-553.
XIV. Jennette JC, Falk RJ. Small-vessel vasculitis. N Engl J Med 1997;337:15121523.
XV. Osaki S. ANCA-associated vasculitis: diagnostic and therapeutic strategy. Allergol Int 2007;56:87-96.

XVI. Vera-Lastra OL. Diagnostic approach to vasculitis. In: Vera-Lastra OL, Halabe Cherem J, eds. Vasculitis. Mexico: Alfil; 2006. pp. 77-99. 128

XVII. Pesci A, Manganelli P. Involvement of the respiratory system an ANCAassociated systemic vasculitides: clinical and pathologic hallmarks and treatment. Drugs 2007;8:25-42.

XVIII. Pagnoux C, Teixeira L. Wegener's granulomatosis. Presse Med 2007;36(5Pt 2):860-874.

XIX. Reinhold-Keller E, Beuge N, Latza U, de Groot K, Rudert H, Nölle B, et al. An interdisciplinary approach to the care of patients with Wegener's granulomatois: long term outcome of 155 patients. Arthritis Rheum 2000;43:10211032.